# Gland Pharma Limited, Units I+II Pashamylaram Site - Inspection Records

Source: https://www.globalkeysolutions.net/companies/gland-pharma-limited-units-iii-pashamylaram-site/a7dffca3-c5cc-4802-9cab-54995e7133ca

> Inspection records and compliance data for Gland Pharma Limited, Units I+II Pashamylaram Site in Hyderabad, None. Access full analysis and detailed observations.

---

## Details

- Name: Gland Pharma Limited, Units I+II Pashamylaram Site
- FEI Number: 3009864167
- City: Hyderabad
- State: None
- Country Name: India
- Address Line 1: 54 55 64 - 68 Plots 42 - 52, Sy No 166; 171 172 - 177 Sangareddy Dist
- Zip Code: None
- Business Operations: API/FDF ANALYTICAL TESTING, FDF MANUFACTURE, PACK

## Related Documents

- [483 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2024-08-02](https://www.globalkeysolutions.net/records/483/gland-pharma-limited-units-iii-pashamylaram-site/ec9c17b8-eaa1-4d9f-aa4a-0631bfca1f54) — source: FDA, date: August 2, 2024
- [483 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2024-08-02](https://www.globalkeysolutions.net/records/483/gland-pharma-limited-units-iii-pashamylaram-site/aed20ec2-46aa-441a-81bc-f5356b9f897b) — source: FDA, date: August 2, 2024
- [483 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2023-08-26](https://www.globalkeysolutions.net/records/483/gland-pharma-limited-units-iii-pashamylaram-site/c2f4d2bb-1f08-4cc0-b659-19378e201a83) — source: FDA, date: August 26, 2023
- [FDA Inspection 1216053 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2023-08-26](https://www.globalkeysolutions.net/records/fda_inspections/gland-pharma-limited-units-iii-pashamylaram-site/955ba795-ebdd-4ebb-861f-16909163e529) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 26, 2023
- [FDA Inspection 1210478 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2023-06-27](https://www.globalkeysolutions.net/records/fda_inspections/gland-pharma-limited-units-iii-pashamylaram-site/cdefda8a-9fac-4c48-90f1-47b5c117ec07) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 27, 2023
- [483 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2019-11-07](https://www.globalkeysolutions.net/records/483/gland-pharma-limited-units-iii-pashamylaram-site/767d64c6-92ff-4f24-8fde-19bd74da6cdc) — source: FDA, date: November 7, 2019
- [FDA Inspection 1109239 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2019-11-07](https://www.globalkeysolutions.net/records/fda_inspections/gland-pharma-limited-units-iii-pashamylaram-site/b1e79e8a-4766-4a82-8ce3-2f50924d5757) — classification: Voluntary Action Indicated (VAI), source: FDA, date: November 7, 2019
- [FDA Inspection 1043371 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2018-02-23](https://www.globalkeysolutions.net/records/fda_inspections/gland-pharma-limited-units-iii-pashamylaram-site/2a89c877-04b5-44c9-bda9-2d69a6bcbb57) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 23, 2018
- [FDA Inspection 944183 - Gland Pharma Limited, Units I+II Pashamylaram Site - 2015-09-18](https://www.globalkeysolutions.net/records/fda_inspections/gland-pharma-limited-units-iii-pashamylaram-site/d77a2750-82df-4a46-854c-8ebea4093694) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 18, 2015

## Related Companies

- [Glenmark Pharmaceuticals Limited](https://www.globalkeysolutions.net/companies/glenmark-pharmaceuticals-limited/66c964bb-f670-493b-ab86-aa8507e68a5d)
- [MassBiologics](https://www.globalkeysolutions.net/companies/massbiologics/fa584e7c-22de-470c-836a-dd3028fae600)
- [Ipca Laboratories Limited](https://www.globalkeysolutions.net/companies/ipca-laboratories-limited/8357cd13-53b4-4e4d-a2a5-54b750096c7a)
- [Dendreon Pharmaceuticals LLC](https://www.globalkeysolutions.net/companies/dendreon-pharmaceuticals-llc/3de4a8e5-8e34-4212-8862-ecd5256c6ffe)
- [Catalent Belgium SA](https://www.globalkeysolutions.net/companies/catalent-belgium-sa/f48653bf-84a2-4aeb-bdc3-ca2d0cc4fdf2)
- [NATCO Pharma Limited](https://www.globalkeysolutions.net/companies/natco-pharma-limited/4c97e2d8-0023-4572-966f-d396e8fecc05)
- [Charles River Laboratories Inc](https://www.globalkeysolutions.net/companies/charles-river-laboratories-inc/876b68d9-6285-4039-8732-05f876b5d911)
- [Seqirus Inc](https://www.globalkeysolutions.net/companies/seqirus-inc/0debebe6-6f57-40d3-abf9-5914fb18b58a)
- [Nephron Sc Inc](https://www.globalkeysolutions.net/companies/nephron-sc-inc/2dadfd52-37b7-4da6-9885-864d470c1b18)
- [Glenmark Pharmaceuticals Limited](https://www.globalkeysolutions.net/companies/glenmark-pharmaceuticals-limited/8a329d32-4a7d-4062-8336-1a4c9455759e)

## Related Officers

- [Investigator](https://www.globalkeysolutions.net/people/michael-a-charles/f83241f0-ae3b-4535-ac03-e790bbf666ca)
- [Dipesh K. Shah](https://www.globalkeysolutions.net/people/dipesh-k-shah/d4df4040-13d1-477b-8c21-4c8e5b3fc5b9)
- [Consumer Safety Officer](https://www.globalkeysolutions.net/people/jeffrey-p-raimondi/7576ca4e-d9e8-4015-9ae6-9498e76058d3)
- [Investigator](https://www.globalkeysolutions.net/people/roger-f-zabinski/87e05838-f8b5-489a-8db7-6669e68a2c2e)